Literature DB >> 8262135

Cytochemical localization of actin and myosin aggregates in interphase nuclei in situ.

K Milankov1, U De Boni.   

Abstract

Biochemical and ultrastructural studies on isolated nuclear compartments have previously shown actin and myosin to be constituents of interphase nuclei. In the present work, immunocytochemistry, in conjunction with confocal microscopy and ultrastructural immunogold techniques, shows that interphase nuclei of intact dorsal root ganglion neurons and of PC12 cells contain actin and myosin. Nuclear actin was observed to be distributed throughout the nucleoplasm occurring as distinct aggregates. Frequently, prominent actin aggregates were associated with the nucleolar periphery, often near nucleolar satellites. Ultrastructurally, actin was observed to be associated with linear, electron-dense structures, putatively identified as chromatin fibers, extending from nucleoli. Use of three antibodies against subclasses of alpha-actin isoforms revealed that nuclear actin is more closely related to alpha-sarcomeric actin than to alpha-smooth muscle actin. Those aggregates associated with the nucleolus were found to be in the polymerized F-actin form, in a small fraction of neurons, as assessed by FITC-phalloidin. A myosin-like antigen was also observed to occur as intranuclear aggregates. Quantitative assays of the distribution of actin and myosin aggregates by nearest neighbour analysis indicated a distribution characterized as uniform and failed to reveal statistically significant associations between any set of aggregates. The evidence presented herein indicates that actin and myosin are constituent proteins of interphase nuclei in situ of both normal mammalian and transformed mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262135     DOI: 10.1006/excr.1993.1301

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

Review 1.  Half a century of "the nuclear matrix".

Authors:  T Pederson
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

2.  Deciphering the nuclear import pathway for the cytoskeletal red cell protein 4.1R.

Authors:  P Gascard; W Nunomura; G Lee; L D Walensky; S W Krauss; Y Takakuwa; J A Chasis; N Mohandas; J G Conboy
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

3.  Chromatin organization measured by AluI restriction enzyme changes with malignancy and is regulated by the extracellular matrix and the cytoskeleton.

Authors:  Andrew J Maniotis; Klara Valyi-Nagy; John Karavitis; Jonas Moses; Viveka Boddipali; Ying Wang; Rafael Nuñez; Suman Setty; Zarema Arbieva; Mina J Bissell; Robert Folberg
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

4.  Cytochalasin D and latrunculin affect chromosome behaviour during meiosis in crane-fly spermatocytes.

Authors:  A Forer; J D Pickett-Heaps
Journal:  Chromosome Res       Date:  1998-11       Impact factor: 5.239

5.  NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation.

Authors:  T A Kim; J Lim; S Ota; S Raja; R Rogers; B Rivnay; H Avraham; S Avraham
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

6.  Structural protein 4.1 in the nucleus of human cells: dynamic rearrangements during cell division.

Authors:  S W Krauss; C A Larabell; S Lockett; P Gascard; S Penman; N Mohandas; J A Chasis
Journal:  J Cell Biol       Date:  1997-04-21       Impact factor: 10.539

7.  Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations.

Authors:  Darin McDonald; Gustavo Carrero; Christi Andrin; Gerda de Vries; Michael J Hendzel
Journal:  J Cell Biol       Date:  2006-02-13       Impact factor: 10.539

8.  The karyosphere capsule in Rana temporaria oocytes contains structural and DNA-binding proteins.

Authors:  Nadya Ilicheva; Olga Podgornaya; Dmitry Bogolyubov; Galina Pochukalina
Journal:  Nucleus       Date:  2018       Impact factor: 4.197

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.